In the most recent Clinical Practice Guidelines for systemic treatment of breast cancer (Japanese Breast Cancer Society; 2018 edition [31]), continuation of anti-HER2 therapy is recommended as third-line or later in metastatic settings. This evidence concerns the gene ERBB2 and breast carcinoma.